SLN (Silence Therapeutics) Days Sales Outstanding: (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SLN Silence Therapeutics PLC SLN
36 GF Score
Price $12.24
GF Value $0.12
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Silence Therapeutics Days Sales Outstanding?

Silence Therapeutics's average Accounts Receivable for the three months ended in Jun. 2026 was $0.00 Mil. Silence Therapeutics's Revenue for the three months ended in Jun. 2026 was $0.00 Mil.

The historical rank and industry rank for Silence Therapeutics's Days Sales Outstanding or its related term are showing as below:

SLN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 5.32   Med: 383.83   Max: 16574.32
Current: 30.47

During the past 13 years, Silence Therapeutics's highest Days Sales Outstanding was 16574.32. The lowest was 5.32. And the median was 383.83.

SLN's Days Sales Outstanding is ranked better than
82.86% of 840 companies
in the Biotechnology industry
Industry Median: 69.01 vs SLN: 30.47

Silence Therapeutics's Days Sales Outstanding declined from Jun. 2025 (25.35) to Jun. 2026 ().

Silence Therapeutics  (NAS:SLN) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Silence Therapeutics Days Sales Outstanding Related Terms

Silence Therapeutics Days Sales Outstanding Historical Data

* Premium members only.

The historical data trend for Silence Therapeutics's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Silence Therapeutics Days Sales Outstanding Chart

Silence Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Days Sales Outstanding
Get a 7-Day Free Trial Premium Member Only Premium Member Only 432.97 13.11 7.99 5.32 633.19

Silence Therapeutics Quarterly Data
Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.35 32.63 75.26 - -

SLN vs OBX, LXRX, ABUS: Days Sales Outstanding Comparison

For the Biotechnology subindustry, Silence Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Silence Therapeutics Days Sales Outstanding vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Silence Therapeutics's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Silence Therapeutics's Days Sales Outstanding falls into.


SLN
36GF Score
Silence Therapeutics PLC SLN
Days Sales Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Silence Therapeutics Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Silence Therapeutics's Days Sales Outstanding for the fiscal year that ended in Dec. 2025 is calculated as

Days Sales Outstanding (A: Dec. 2025 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2024 ) + Accounts Receivable (A: Dec. 2025 )) / count ) / Revenue (A: Dec. 2025 )*Days in Period
=( (0.971999999999 + 0) / 1 ) / 0.560306310713*365
=0.971999999999 / 0.560306310713*365
=633.19

Silence Therapeutics's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding (Q: Jun. 2026 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Mar. 2026 ) + Accounts Receivable (A: Jun. 2026 )) / count ) / Revenue (A: Jun. 2026 )*Days in Period
=( ( + ) / 1 ) / 0*365 / 4
=0 / 0*365 / 4
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Silence Therapeutics (SLN) Overvalued in 2026?

Based on GuruFocus' analysis, Silence Therapeutics stock appears to be overvalued. The current stock price of $12.24 is trading 10100% above its estimated GF Value™ of $0.12. GuruFocus considers Silence Therapeutics to be Significantly Overvalued.

Key valuation signals for SLN:

  • Days Sales Outstanding:
  • GF Value™: $0.12 vs. price of $12.24 (10100% above fair value)
  • GF Score™: 36/100 with 8 warning signs

No single metric tells the full story. See the SLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Silence Therapeutics Business Description

Other Exchanges SLNCF:USAXRP2:Germany
Address 12 Hammersmith Grove, London, GBR, W6 7AP
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
36GF Score

Get the complete analysis for SLN

Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.24
Price
$0.12
GF Value